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QUALITY OF LIFE PROFILE OF MEN AT-RISK
FOR PROSTATE CANCER:THE FIT AND THE
WORRIED WELL 
Kulkarni SG1,Watkins Bruner D1, Babb J2, Uzzo R2,
Konski A2, Lai JS3, Cella D3
1Fox Chase Cancer Center, Cheltenham, PA, USA; 2Fox Chase
Cancer Center, Philadelphia, PA, USA; 3Evanston
Northwestern Healthcare, Evanston, IL, USA
OBJECTIVES: Men’s motivation to attend a Prostate
Cancer Risk Assessment Program (PRAP) is under study.
Previous PRAP work shows motivation to be unrelated
to risk-knowledge and perceptions. This study assesses
differences in quality of life proﬁles between two cohorts;
men “at-risk” for prostate cancer (PC); and “normal”
men without known risk of PC. METHODS: Functional
Assessment Cancer Therapy (FACT) sub-scale scores
were compared between cohorts; 331 men participating
in PRAP in the NE United States and 456 men with com-
plete FACT data, from an internet-based survey sample
(1400 men randomly drawn from a demographically 
balanced sample of the United States population)
recruited through Knowledge Networks, Menlo Park,
CA. RESULTS: Three hundred seventy-six (82%) of
“normal” men vs. 142 (43%) of “at-risk” men were Cau-
casian. Mean [median] age was 48.1 [46] for “at-risk”
and 43.5 [42] years for “normal” men. Age and ethnic-
ity were controlled in subsequent analyses. The “at-risk”
group demonstrated higher physical and functional well-
being (PWB/FWB) scores than the “normal” group (p <
0.0001). Analyses showed that the effect of PC risk on
emotional well-being (EWB) depended on subject’s age (p
< 0.027). When separated into 2 groups depending on the
overall median age, both younger (<44 years) and older
(>45 years) “normal” men showed signiﬁcantly higher
EWB scores than “at-risk” men; the difference being more
pronounced among younger men. EWB score did not
depend on the race of the subjects. CONCLUSION:
The results indicate that although the men “at-risk” were
older, they report being more physically ﬁt than the
younger “normal” group but had poorer EWB. Since risk
knowledge and perceptions have been poor predictors of
motivation to screen, it may be that motivation is associ-
ated with an emotional “gestalt” related to risk and a
desire to stay ﬁt to overcome risk.
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FEAR OF CANCER RECURRENCE AFTER
TREATMENT FOR PROSTATE CANCER: DATA
FROM CAPSURE
Mehta SS1, Lubeck DP2, Pasta DJ2,Ye J2, Carroll P2
1TAP Pharmaceutical Products Inc, Lake Forest, IL, USA;
2University of California, San Francisco, San Francisco, CA,
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OBJECTIVES: Fear of cancer recurrence has been well
documented for colorectal cancer, breast cancer and bone
marrow transplantation. Limited information exists for
prostate cancer. This study describes fear of cancer recur-
rence (FOCR) in patients undergoing radical prostatec-
tomy (RP) radiation (XRT) and brachytherapy (BT) as
prostate cancer treatment. METHODS: Five hundred
twenty-seven patients who underwent initial treatment
(RP = 328, XRT = 56, BT = 143) were identiﬁed from
CaPSURE, a national longitudinal registry of men with
prostate cancer. Patients in this analysis completed at least
one pretreatment and two post-treatment health related
quality of life (HRQOL) questionnaires and had complete
clinical information. HRQOL was assessed using the SF-
36 and the UCLA Prostate Cancer Index (PCI). FOCR
was assessed with a ﬁve-question scale and was described
at baseline and after treatment. All questionnaires at each
time interval were used to calculate the cross-sectional
mean FOCR score. Linear regression was performed to
determine predictors of FOCR. RESULTS: RP patients
were younger (mean 61.2) than XRT (mean 71.6) and 
BT (mean 69.3) patients. Clinical characteristics among
groups were similar except mean PSA, which was higher
for XRT (8.3) as compared to RP (5.7) and BT (6.2).
Mean FOCR scores were similarly low pretreatment
(more fear) for RP (64.1), XRT (60.4) and BT (62.3),
increased after treatment (less fear) for RP (77.4), XRT
(72.9) and BT (68.9) but did not change substantially
over 24 months thereafter. Regression revealed that only
general health was a signiﬁcant predictor of FOCR. No
other general or disease speciﬁc HRQOL domains or 
clinical characteristics were signiﬁcant predictors. CON-
CLUSIONS: Undergoing treatment for prostate cancer
decreases the FOCR that patients experience; however,
fear level does not change substantially over time. General
health is the strongest predictor of FOCR and thus eval-
uation of this one domain is important for understanding
overall HRQOL outcomes in prostate cancer patients.
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DIFFERENCES IN HUSBAND/WIFE
PREFERENCES AND UTILITIES FOR PROSTATE
CANCER THERAPIES
Bruner DW1, Hanlon A1, Kulkarni S1, Mazzoni S1, Linton S1,
Konski A2, Pollack A2, Greenberg R2, Beck JR2
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OBJECTIVE: This pilot study compared the preferences
and utilities for impotence and incontinence associated
with prostate cancer (PC) treatments between men with
PC and their wives. Several studies have shown little 
congruence between stated and observed preferences. We
hypothesize that spousal inﬂuence may be a signiﬁcant
predictor of observed, versus stated, preferences.
METHODS: Seven husband/wife dyads were recruited
from radiotherapy and urology follow-up clinics. Each
spouse was interviewed without the other present, using
the Time Trade-Off Technique. RESULTS: The husband-
wife dyads demonstrated disparate preferences 50% of
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the time. Whereas 43% and 71% of husbands stated they
would be willing to give up >6mos of a 7-year survival
to avoid a 40% and 80% risk of impotence, respectively,
only 14% of wives would be willing for their husbands
to give up to 6mos of life to preserve potency at any level
of risk. For incontinence 14% and 29% of husbands vs.
0 and 14% of wives stated they would be willing to give
up, or have their husband give up, >6mos of a 7-year sur-
vival to avoid a 10% and 30% risk of incontinence,
respectively. When surgery, radiotherapy and watchful
waiting (WW) were presented with the same life ex-
pectancy but a 99% risk of impotence with the ﬁrst two
options and potency with the latter, 57% of husbands 
vs 14% of wives chose WW. When the same treatment
options were presented with the same life expectancy but
a 99% risk of incontinence with the ﬁrst 2 options and
urinary continence with the latter, 71% of husbands vs
14% of wives chose WW. CONCLUSION: Wives had a
higher utility than husbands for any treatment option vs.
WW, that prolongs the husbands life regardless of level
of risk of quality of life decrements. Wives’ preferences
were more congruent with observed (vs. stated) prefer-
ences of the husbands.
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DEVELOPING A MEASUREMENT STRATEGY
FOR PATIENT-REPORTED OUTCOMES:
FINDINGS FROM THE NCI’S CANCER
OUTCOMES MEASUREMENT WORKING GROUP
Snyder C1, Lipscomb J1, Gotay CC2
1National Cancer Institute, Bethesda, MD, USA; 2University of
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OBJECTIVES: The National Cancer Institute established
the Cancer Outcomes Measurement Working Group
(COMWG) in 2001 to assess the state of the science of
cancer outcomes assessment and to identify areas requir-
ing further research to move the ﬁeld forward. During this
session, we will focus on COMWG ﬁndings related to
designing a patient-reported outcomes (PRO) measure-
ment strategy. METHODS: As part of the COMWG’s
mission, literature reviews of PRO studies in breast, col-
orectal, prostate, and lung cancer were conducted and the
performance of different measurement strategies (generic,
general cancer, cancer site-speciﬁc, unidimensional instru-
ments) were compared. Also, the role of modern psycho-
metric techniques was explored. RESULTS: In designing
a measurement strategy, there is often a trade-off between
comparability and sensitivity. The ability to compare 
and contrast ﬁndings across studies is enhanced when
more generic and widely-used instruments are employed.
However, using a speciﬁc instrument targeted to the 
particular dimensions hypothesized to differ between
groups can enhance sensitivity. Targeted unidimensional
measures were more effective at identifying differences
between groups than generic and general cancer mea-
sures. The importance of using targeted measures that
will be effective in identifying differences between groups
was felt by many COMWG investigators to outweigh the
potential usefulness of adopting a core set of measures 
to promote comparability, although, given sufﬁcient
resources, including both kinds of measures could be
useful. In the future, the use of modern psychometric
techniques, including item response theory, may render
moot the debate between sensitivity and comparability.
As item banks and computer-adaptive assessments are
developed, speciﬁc targeting of items can occur and,
because all items are calibrated using a common metric,
comparability can be promoted. CONCLUSIONS: In
designing a measurement strategy, the relative perfor-
mance of the different approaches requires consideration.
Modern psychometric techniques might contribute to
designing a measurement strategy that provides both 
sensitivity and comparability.
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HEALTH-RELATED QUALITY OF LIFE BURDEN
OF HEAD AND NECK CANCER
Lee JM1, Botteman MF1, Stephens JM1, Kornﬁeld T2,
Gramegna P3, Redaelli A3
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OBJECTIVE: To examine the health-related quality of
life (HRQL) burden of head and neck cancer (HNC) and
HRQL issues related to its treatment. METHODS: A
computerized, systematic literature search was conducted
of the English-language literature published between
1990 and 2002. Augmenting the electronic identiﬁca-
tion of articles, manual searches were conducted of the
retrieved article bibliographies and appropriate confer-
ence proceedings (1999-2002). Type of study and 
analyses conducted, speciﬁc domains affected, factors
associated with short- and long-term HRQL, and impact
of treatment modality were examined. RESULTS: Of 851
abstracts screened, 97 articles met selection criteria and
were reviewed in detail. Forty-six were prospective, lon-
gitudinal studies; 51 were post-treatment studies with no
baseline data. Less than one-ﬁfth of the studies included
multivariate analysis. Before treatment, HNC patients
have poorer HRQL than age-matched controls in emo-
tional, physical, and social well-being. Impacts are greater
among younger age groups. Treatment especially affects
emotional, physical, and social well-being, pain, and
eating ability. Important predictors of HRQL include
speech and eating ability. Radiotherapy, chemotherapy
and surgery have acute, domain-speciﬁc impacts on
patient HRQL that are distinct from long-term impacts.
Emotional well-being remains unchanged or improves
with time, while eating ability worsens in the long-term.
Physical well-being worsens in the short-term with radio-
therapy/chemotherapy and in the long-term with surgery.
CONCLUSIONS: HNC and its treatment substantially
impact the HRQL of patients. Patients typically experi-
ence decreased HRQL during or shortly after treatment,
but then improved HRQL in the longer term. Future
studies should include multivariate analyses to control for
